Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

20181,299 citationsJournal Articlebronze Open Access

Authors

Hussein A. Tawbi · The University of Texas MD Anderson Cancer Center

Peter Forsyth · Moffitt Cancer Center

Alain P. Algazi · University of California, San Francisco

Omid Hamid · Angeles Clinic and Research Institute

F. Stephen Hodi · Dana-Farber Cancer Institute

Stergios J. Moschos · University of North Carolina at Chapel Hill

Nikhil I. Khushalani

Abstract

Nivolumab combined with ipilimumab had clinically meaningful intracranial efficacy, concordant with extracranial activity, in patients with melanoma who had untreated brain metastases. (Funded by Bristol-Myers Squibb and the National Cancer Institute; CheckMate 204 ClinicalTrials.gov number, NCT02320058 .).

Topics & Keywords

Cancer Immunotherapy and Biomarkers Brain Metastases and Treatment CAR-T cell therapy research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 379, Issue 8, pp. 722-730

DOI: 10.1056/nejmoa1805453

Field-Weighted Citation Impact: 62.40